Active, not recruitingPhase 3NCT03844048
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Venetoclax(drug)
- Enrollment
- 165 target
- Eligibility
- All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- University of Arizona Cancer Center - Tucson /ID# 210548, Tucson, Arizona, United States
- UCLA Santa Monica Hematology Oncology /ID# 210551, Los Angeles, California, United States
- Ingalls Memorial Hosp /ID# 210553, Harvey, Illinois, United States
- Dana-Farber Cancer Institute /ID# 215360, Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132, Ann Arbor, Michigan, United States
- Dartmouth-Hitchcock Medical Center /ID# 210555, Lebanon, New Hampshire, United States
- Swedish Medical Center - Seattle /ID# 213120, Seattle, Washington, United States
- Royal Prince Alfred Hospital /ID# 239557, Camperdown, New South Wales, Australia
- St George Hospital /ID# 225589, Kogarah, New South Wales, Australia
- Liverpool Hospital /ID# 225591, Liverpool, New South Wales, Australia
- Peter MacCallum Cancer Ctr /ID# 210559, Melbourne, Victoria, Australia
- Fiona Stanley Hospital /ID# 239480, Murdoch, Western Australia, Australia
- Perth Blood Institute Ltd /ID# 225592, Nedlands, Western Australia, Australia
- Duplicate_Medizinische Universitaet Graz /ID# 223817, Graz, Styria, Austria
- Cliniques Universitaires UCL Saint-Luc /ID# 224327, Brussels, Brussels Capital, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03844048 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics